TABLE 2

Kinetic parameters of drugs for hepatic and renal clearance

CLuptake, hepCLuptake, sliceafubRBbfBCLh, int, allbCLsec, int, allbScaling FactorcCLsecb
ml · min1 · kg1ml · min1 · kg1ml · min1 · kg1
Rosuvastatin15.13.300.120.690.17410427.08.23.92
Pravastatin13.8d0.4470.550.560.98923.316.6379.47
Pitavastatin446d0.9570.00520.580.0094113.343.50.03
Valsartan18.92.380.040.550.0738.951.800.70.129
Olmesartan12.13.130.010.550.01818.611.13.50.204
Trichlormethiazide1.010.290.550.52710.7114.54
PAH0.4820.830.701.19N.A.N.A.13.6
Fexofenadine0.347e0.310.550.5641.524.40.658
Methotrexate0.168f0.370.830.4461.408.31.13
Benzylpenicillin0.5080.560.660.8435.71115.26
Candesartan44.80.00270.550.00567.2
Atorvastatin169d0.05110.610.084329
Fluvastatin351d0.00370.520.0073760
Cerivastatin746g0.0070.580.012485
  • CLuptake, hep, uptake clearance by human hepatocytes; CLuptake, slice, corrected saturable uptake clearance by human kidney slices; CLh, int, all, observed hepatic overall intrinsic clearance; CLsec, int, all, observed renal secretion overall intrinsic clearance; CLsec, observed renal secretion clearance; N.A., not applicable.

  • a Saturable uptake clearance was corrected by uptake of benzylpenicillin. The details of this estimation are described in the text and Table 1.

  • b References cited are listed in Supplemental Table 1.

  • c Scaling factors were calculated by dividing CLsec, int, all by CLuptake, slice.

  • d Data from Watanabe et al. (2010a).

  • e Data from Matsushima et al. (2009).

  • f Data from Nozaki et al. (2007b).

  • g Data from Shitara et al. (2003).